Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Phase III Amyloidosis Failure Prothena Slashes Workforce In Restructuring

Executive Summary

In the backlash following the failure of its late-stage amyloidosis drug, Prothena has announced it will cut 57% of its workforce as part of a restructuring plan.

You may also be interested in...

AstraZeneca Goes All In On AL Amyloidosis With Caelum Acquisition

AstraZeneca’s recently-acquired Alexion unit is paying $150m upfront to buy the remainder of Caelum Biosciences and its late-stage therapy for light chain  amyloidosis, a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys.

Roche in $600m deal for Parkinson's antibody program

Roche is paying Elan spin-out Prothena $45m in the near term as part of a new collaboration to develop and commercialize antibodies that target alpha-synuclein. The agreement includes PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and is expected to enter Phase I trials in 2014.

Prothena spins out of Elan

Elan has carried out the demerger of its drug discovery activities into a new company, which it has named Prothena. The operation, which the firm announced back in August when its Phase III Alzheimer's antibody, intravenous bapineuzumab, partnered with Janssen and Pfizer, failed in a pivotal trial, conducted by Janssen (, 7 August 2012, 13 August 2012 and 15 August 2012).


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts